Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270) Logs Preliminary Q4 Revenue of KRW 1.06T, Rising 178.01% YoY

Posted on February 27, 2025July 16, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Logs Preliminary Q4 Revenue of KRW 1.06T, Rising 178.01% YoY

Source: Financial Supervisory Service Dart System / 2025-02-25

Disclosure Type: Preliminary Earnings Release (Consolidated)

💡 3-Second Summary

Celltrion has released its preliminary Q4 2024 consolidated results, reporting revenue of approximately KRW 1.06T, up 178.01% year-on-year, and bringing its cumulative annual revenue to KRW 3.56T.

📊 1. [Key Disclosure Content & Major Figures Summary]

  • Q4 2024 Preliminary Financial Performance (Quarterly):
    • Revenue: KRW 1,063,649M (approx. KRW 1.06T) / Up 20.60% QoQ, Up 178.01% YoY
    • Operating Profit: KRW 196,404M (approx. KRW 196.4B) / Down 5.43% QoQ, Up 966.08% YoY
    • Income Before Income Taxes: KRW 273,993M (approx. KRW 274B) / Up 53.71% QoQ, Turned to Black YoY
    • Net Profit: KRW 235,569M (approx. KRW 235.6B) / Up 180.13% QoQ, Up 51,901.99% YoY
  • FY 2024 Cumulative Preliminary Performance (Annual):
    • Cumulative Revenue: KRW 3,557,304M (approx. KRW 3.56T) / Up 63.45% compared to previous year (KRW 2,176,432M)
    • Cumulative Operating Profit: KRW 492,016M (approx. KRW 492B) / Down 24.48% compared to previous year (KRW 651,481M)
    • Cumulative Income Before Income Taxes: KRW 576,117M (approx. KRW 576.1B) / Down 14.15% compared to previous year (KRW 671,096M)
    • Cumulative Net Profit: KRW 418,883M (approx. KRW 418.9B) / Down 22.39% compared to previous year (KRW 539,707M)
  • Administrative and Explanatory Notes:
    • These figures represent the company’s internal preliminary calculations and may be modified depending on the external auditor’s final results.
    • No specific reasons for the performance changes were provided in this regulatory filing.

📈 2. [Expert Perspective: What This Means for Investors]

  • Quarterly Revenue and Operating Trends: Celltrion’s preliminary Q4 consolidated revenue reached approximately KRW 1.06T, representing a 20.60% expansion QoQ and 178.01% YoY. Preliminary operating profit for the quarter was approximately KRW 196.4B, marking an increase of 966.08% YoY, though it decreased by 5.43% compared to the prior quarter.
  • Contrasting Cumulative Figures: The preliminary cumulative revenue of KRW 3.56T reflects a 63.45% expansion compared to the prior fiscal year. Conversely, cumulative operating profit (approx. KRW 492B) and net profit (approx. KRW 418.9B) decreased by 24.48% and 22.39% respectively, exhibiting diverging trends between annual top-line growth and cumulative bottom-line indicators.
  • Absence of Explanation for Performance Variations: This disclosure only provides numerical data and does not state the specific administrative or operational drivers behind the fluctuations in quarterly and cumulative performance.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has disclosed its preliminary consolidated earnings for Q4 2024. The filing provides preliminary figures showing quarterly revenue of approximately KRW 1.06T and cumulative annual revenue exceeding KRW 3.56T, outlining the company’s annual financial scale to the market.

The primary check point for investors moving forward is the formal verification of these preliminary metrics against the finalized, audited financial results. Because these figures are based on internal calculations prior to the completion of the external audit, investors must compare them with the finalized financial statements in the upcoming audit report.

Additionally, while cumulative revenue increased, cumulative operating profit declined by 24.48% compared to the previous year. As the filing does not state the drivers for this decline, investors are advised to objectively monitor upcoming audited periodic reports to review verified, finalized financial details once the complete annual filings are published.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.

S

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Signs MOA for New Plant in Yesan, South Korea, Agreeing to KRW 300 Billion Finished Drug Product Facility
Next Post: [Disclosure] Isu Petasys (007660) Designated as Unfaithful Disclosure Corporation; Hit with 6 Penalty Points and KRW 60M Fine Following M&A Cancellations

Related Posts

[Disclosure] Hanwha Aerospace (012450) – (Correction) Decision to Acquire Equity-Linked Bonds (Overair Convertible Note Matured Without Repayment or Conversion) Disclosures
[Disclosure] Celltrion (068270) Secures Final EC Marketing Authorization for RoActemra Biosimilar ‘Avtozma’ Disclosures
[Disclosure] Hanwha Ocean (042660) Decides KRW 268B New Facilities Investment to Enhance Construction Efficiency Disclosures
[Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in Europe Disclosures
[Disclosure] KRX Suspends Jusung Engineering (036930) Stock Futures Following Demerger Announcement: Trading Set to Resume on May 3 Semiconductors
[Disclosure] Celltrion (068270) Obtains Marketing Authorization from Korean MFDS for ‘Steqeyma (CT-P43)’ Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme